What are the Clinical Outcomes of KRAS G12C Inhibitors?
The clinical outcomes of KRAS G12C inhibitors have been encouraging, particularly in patients with NSCLC. In clinical trials, sotorasib has demonstrated significant antitumor activity and manageable safety profiles. Patients have shown improved progression-free survival and overall response rates compared to standard therapies.
